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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S32malnutrition, only 1 (3.7%) had an improvement in nutritional status and
one child Stage IV Burkitt's lymphoma succumbed to sepsis.
Conclusion: A signiﬁcant proportion of children with malignancy in the
developing world start treatment with under nutrition. Childrenwith mild
and moderate malnutrition show improvement in nutritional status with
nutritionist intervention. Children with severe under nutrition at the start
of therapy continue to be a challenge in the developing world. Nutritional
assessment by nutritionist throughout therapy for malignancy is essential
for appropriate nutrition intervention.
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CYTOMEGALOVIRUS (CMV) VIRAEMIA AND DISEASE IN CHILDREN
WITH HAEMATOLOGICAL MALIGNANCIES UNDERGOING
CONVENTIONAL CHEMOTHERAPY: A LARGE STUDY FROM A REFERRAL
CANCER CENTRE IN INDIA
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Biswas 2, Rohini Kelkar 2, Tushar Vora 1, Maya Prasad 1, Girish Chinnaswamy1,
Gaurav Narula 1, Brijesh Arora 1, Shripad Banavali 1. 1Department of Medical
Oncology (Pediatric), Tata Memorial Hospital, India; 2Department of
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Background: There is paucity of data on CMV infection in haematological
malignancies in non-transplant settings, which is critical to plan timely
therapy and reduce morbidity and mortality.
Methods: Between January 2008 and November 2015, we screened all
children with haematolymphoid malignancies having unexplained fever,
prolonged cytopenia, hemophagocytic lymphohistiocytosis (HLH) or clin-
ical CMV disease, for CMV using RT-PCR. CMV-positive episodes were
analysed for clinical features and response to treatment.
Results: Seventy children had CMV infection. Of them, 61 (87%) had CMV
DNAemia and 9 (13%) had CMV disease. The primary diagnoses were ALL
(n¼59, 85%), AML (n¼2), NHL (n¼6), Hodgkin's lymphoma (HL, n¼2), and
CML (n¼1). The median age was 12 years. For ALL patients, CMV DNAemia
and disease occurred mostly during either consolidation (46%) or main-
tenance (36%) phase. The most common presenting feature of CMV
infection was unexplained fever without focus (n¼68, 97%). Of these, 37
(54.5%) had no associated cytopenias. All became afebrile at a median
ganciclovir duration of 3 days (range, 2-7 days). The rest (n¼31, 45.5%) had
unexplained fever with cytopenia, and all recovered after a variable period
of 3 to 28 days (median, 15 days). Two of them developed HLH and were
treated with HLH protocol along with antiviral therapy. For patients with
CMV viraemia, CMV titres became undetectable after amedian period of 17
days (range 7-34 days). Five had relapse of CMV-viraemia: two had com-
plete response and survived, while 3 died of primary malignancy during
CMV therapy. For the 9 with CMV disease, their primary diagnoses were
ALL (n¼6), AML (n¼1), HL (n¼1), and Burkitt's Lymphoma (n¼1). Disease
sites were chorioretinitis (n¼2), pneumonitis (n¼3), gastrointestinal dis-
ease (n¼2) and encephalitis (n¼1). In addition, one patient had both GI
infection and CMV encephalitis. After treatment with I.V. ganciclovir, 5
patients recovered fully, 2 died of CMV, one died of progressive primary
disease and one was lost to follow up. Out of the 2 children with cho-
rioretinitis, one had permanent visual deﬁcits while the other recovered
with normal vision.
Conclusion: CMV DNAemia and disease are common in children with
haematological malignancies on standard-dose therapy. ALL patients were
more commonly affected, usually during the consolidation phase of ALL
therapy. Most presented with unexplained fever with or without pro-
longed cytopenias. Approximately 15% can progress to HLH or CMV disease
if not detected in time. Timely detection and therapy with ganciclovir is
curative in most children.
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PROCEDURAL SEDATION IN PEDIATRIC ONCOLOGY e A RANDOMIZED
COMPARATIVE TRIAL OF KETAMINE e MIDAZOLAM COMBINATION VS
PROPOFOL
C. Varsha, Manas Kalra, Anita S. Bakshi, Geeta Mandhani, Amita
Mahajan. Apollo Center for Advanced Pediatrics, Indraprastha Apollo
Hospitals, Delhi, IndiaBackground: Procedural pain is a signiﬁcant quality of life issue in chil-
dren undergoing treatment for childhood cancer. Painful procedures are
therefore done under sedation wherever feasible. Ideal sedation should be
safe, effective, have prompt induction and smooth recovery. Both keta-
mine-midazolam and propofol are frequently used in this setting and have
been reported to be efﬁcacious. However, there are no published pro-
spective, randomized comparative trials (RCT) directly comparing these
two groups when performed by non- anesthesiologists.
Objective: To compare ketamine+midazolam (Group A) and propofol
(Group B) as sedative agents for intrathecal chemotherapy with regards to
efﬁcacy, side effect proﬁle, time to induction, time to recovery and
smoothness of recovery.
Methods: A partially-blinded, RCTwas conducted over a period of one year
between July 2015-July 2016 after institutional ethics committee approval.
Children aged 1-12 years requiring intravenous sedation for intrathecal
chemotherapy were included. Children with known cardiovascular or
respiratory disturbances, presence of neurological abnormalities and he-
patic/renal failure were excluded. Patients were allocated to the two
treatment arms using computer generated randomization tables after
obtaining written, informed consent. The initial doses used were, keta-
mine at 2mg/kg, midazolam at 0.2 mg/kg and propofol at 2.5mg/kg as per
standard recommendations. The patient, parents and the person analyzing
the data were blinded. Time to sedation, dose required for effective
sedation, depth of sedation (using Modiﬁed Ramsey scale), vital parame-
ters intra-procedure, time to recovery, smoothness of recovery and
emergence phenomenon were documented.
Results: One hundred and ﬁve patients were enrolled (Group A: 53, Group
B: 52). Seven patients had failure of sedation (all were in Group B). 9 pa-
tients in group A and 35 patients in group B required top up over and above
the initial administered doses. Mean time to sedation in group B was
shorter than in group A (p¼0.001).Mean heart rate in group A was higher
than in group B (p¼0.000). Transient drop in saturation was noted in 9
patients in group A and in 14 patients in group B. Mean depth of sedation
in group A was greater than in group B (p¼0.001). Mean time to recovery
in group B was shorter than in group A (p¼0.000). Emergence symptoms
were experienced by 29 patients in group A and 5 patients in group B
(p¼0.000)
Conclusion: Ketamine-Midazolam combination appears to be safer and
more effective. However, propofol has a signiﬁcantly faster onset, quicker
recovery with a smoother emergence from sedation, but at the recom-
mended initial doses it provides inadequate sedation.
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AN AUDIT OF CENTRAL VENOUS ACCESS DEVICES (CVADS) IN PEDIATRIC
ONCOLOGY
Deepankar Bhattacharya, Shalini Mishra, Sandeep Jain, Gauri Kapoor. Rajiv
Gandhi Cancer Institute and Research Centre, New Delhi, India
Background: Central Venous access devices (CVADs) usage comprises an
integral component for management of childhood malignancies. The
purpose of this study was to evaluate our experience of CVADs with regard
to their feasibility, safety, and complications.
Material andmethods: A retrospective analysis of all CVADs [peripherally
inserted central catheter (PICCs), chemoports (port-a-cath) and Hickman
catheters]placed in Pediatric Oncology department of our institute from
June 2015 to May 2016, was done. All procedures were performed under
ultrasound guidance ± image intensiﬁer. Information was collected
regarding demographic details, catheter life (number of catheter days), and
adverse events (AE) [namelyinfection, blockage, extrusion, port-tip
migration and exit site skin excoriation]. Risk factors for AE were analysed
which included underlying disease, age of patient, type of CVAD and
number of catheter days.
Results: During the study interval, 147 CVADs were placed in 138 patients
with a median age of 7.5 years (range 10 months -18 years) and a male:
female ratio of 100:38. The CVADs included 117 PICCs, 23 chemoports and
7 Hickman catheters. Three patients who came only for PICC insertion
were excluded from analysis. The remaining 135 patients had a follow-up
of 151 median catheter days (range 8 e 375 days). Overall incidence of AE
was 0.828/1000 catheter days (19/22,924 catheter days).None of the
